Loading stock data…
ACADIA Pharmaceuticals Inc. (ACAD)
$27.58-0.44 (-1.57%)
After Hours$27.58+0.00 (+0.00%)· Last close Sep 8
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ACADIA Pharmaceuticals Inc. in the Healthcare sector is trading at $27.58 with a market capitalization of $4.8B. Wall Street consensus targets $34.00 (20 analysts), implying a +23.3% move over the next 12 months. The stock is currently 11% below its 52-week high of $30.96, remaining 12.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $307.96M↑ | $268.06M↓ | $283.99M↑ | $278.63M↑ | $264.57M |
| Gross Profit | $279.64M↑ | $243.27M↓ | $257.76M↑ | $256.99M↑ | $243.83M |
| Operating Income | $37.84M↑ | -$4.62M↓ | $17.39M↓ | $35.76M↑ | $32.37M |
| Net Income | $31.50M↑ | $3.64M↓ | $273.57M↑ | $71.78M↑ | $26.67M |
Peer Comparison
JNJUNHPFE
Fundamentals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agon...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.83B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.12%
Volume
Today's trading volume
1.46M
Recent News
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis during a discussion hosted by Canaccord Genuity. Thomas Garner, Acadia’s chief comme
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.
Immunic appoints Elena Ridloff to board of directors
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously held the same role at ACADIA Pharmaceuticals, where she helped raise $600 million in capital and...